ArticleGlobal health, science and practice2015
ARVs: the next generation. Going boldly together to new frontiers of HIV treatment.
Article in Global health, science and practice, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.PLoS medicine · 2015Pooled it
- Joint replacement and human immunodeficiency virus.World journal of virology · 2023Review
- Dolutegravir Suppresses Thermogenesis via Disrupting Uncoupling Protein 1 Expression and Mitochondrial Function in Brown/Beige Adipocytes in Preclinical Models.The Journal of infectious diseases · 2022Article
- Weight gain during pregnancy among women initiating dolutegravir in Botswana.EClinicalMedicine · 2020Article
- Human immunodeficiency virus in total hip arthroplasty.EFORT open reviews · 2020Review
- HIV‑1 integrase inhibitors targeting various DDE transposases: Retroviral integration versus RAG‑mediated recombination (Review).Molecular medicine reports · 2019Review
- Synthesis of a long acting nanoformulated emtricitabine ProTide.Biomaterials · 2019Article
- Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.The Lancet. Global health · 2018Observational
- Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals.Nanomedicine (London, England) · 2018Article
- The impact of a therapeutic exercise intervention on depression and body self-image in HIV-positive women in sub-Saharan Africa.HIV/AIDS (Auckland, N.Z.) · 2018Article
- Long-acting slow effective release antiretroviral therapy.Expert opinion on drug delivery · 2017Review
- The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen.Current opinion in HIV and AIDS · 2017Review
- When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.Current opinion in HIV and AIDS · 2017Review
- A Framework for Health Communication Across the HIV Treatment Continuum.Journal of acquired immune deficiency syndromes (1999) · 2017Review
- ART access-related barriers faced by HIV-positive persons linked to care in southern Ghana: a mixed method study.BMC infectious diseases · 2016Article
- How can we achieve universal access to low-cost treatment for HIV?Journal of virus eradication · 2016Article
- Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?Journal of the International AIDS Society · 2016Article
- Reduced Effectiveness of Contraceptive Implants for Women Taking the Antiretroviral Efavirenz (EFV): Still Good Enough and for How Long?Global health, science and practice · 2015Article
- The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.PLoS medicine · 2015Article
- HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.